Incyte's vision is to become a leading drug discovery and development company by building a proprietary product pipeline of novel small molecule drugs in serious unmet medical needs. Our pipeline is focused in oncology and inflammation and includes compounds in various stages of development. In June 2011 we submitted a New Drug Application (NDA) for our most advanced product candidate, ruxolitinib, for the treatment of myelofibrosis. Incyte's corporate headquarters is located in Wilmington, Delaware. Incyte offers a generous compensation and benefits package and is proud to be an Equal Opportunity Employer.